Skip to content
Open access

LPA genetic variation is associated with type 2 diabetes after adjustment for lipoprotein(a) concentration: results of the Aragon Workers’ health study

P. Corredoira Daniel Bello Álvarez Itziar Lamiquiz Moneo Victoria Marco Benedí Estíbaliz Jarauta M. Laclaustra F. Civeira A. Cenarro
Aug 2026 · Cardiovascular Diabetology · 0 citations

TL;DR

The findings suggest that common LPA variation represented by the 15-SNV genetic score may contribute to T2D risk through mechanisms not fully captured by circulating Lp(a) concentration alone.

Abstract

Epidemiological and Mendelian randomization studies have reported an inverse relationship between lipoprotein(a) [Lp(a)] concentration and type 2 diabetes (T2D), although findings have not been uniform across studies. We hypothesized that genetic variation at the LPA locus may contribute to T2D development beyond circulating Lp(a) concentration alone, and therefore aimed to investigate the association between common LPA variation and incident T2D. We analysed 5058 male participants from the Aragon Workers’ Health Study with approximately 15 years of follow-up. T2D was defined as the presence of antidiabetic treatment or HbA1c ≥ 6.5%. Common LPA single-nucleotide variants (SNVs) with a minor allele frequency ≥ 1% were selected. Several weighted LPA genetic scores were constructed, with the 15-SNV score defined as the primary LPA genetic score and alternative and more restricted scores evaluated in sensitivity analyses. Associations of single LPA variants and LPA genetic scores with incident T2D were assessed using multivariable logistic regression models adjusted for age, body mass index, ln-transformed Lp(a), and a T2D polygenic risk score. False discovery rate correction was applied to account for multiple testing. Robustness was assessed using leave-one-out analyses and Cox proportional hazards models. Among 4744 participants free of T2D at baseline, 578 (12.2%) developed incident T2D. Baseline Lp(a) concentrations were lower in participants who developed incident T2D than in those who remained free of T2D (12.6 [5.0–32.5] versus 17.0 [6.1–40.0] mg/dL; p  < 0.001). No individual LPA SNV remained significantly associated with incident T2D. In contrast, the primary 15-SNV LPA genetic score was associated with incident T2D after adjustment for measured baseline Lp(a) concentration (odds ratio per one-standard-deviation increase 1.17, 95% confidence interval 1.07–1.29; p  = 0.001). The 13-SNV, 12-SNV, 10-coding/splice, and 2-SNV raising-Lp(a) scores were also significantly associated with incident T2D after false discovery rate correction. The association with the 15-SNV LPA genetic score was supported by leave-one-out and Cox analyses. A 15-SNV LPA genetic score was associated with incident T2D after adjustment for measured baseline Lp(a) concentration and a T2D polygenic risk score. These findings suggest that common LPA variation represented by the 15-SNV genetic score may contribute to T2D risk through mechanisms not fully captured by circulating Lp(a) concentration alone.

Read PDF

Similar papers

Open access Sep 2026

Associations of Elevated Lipoprotein(a) with C-Reactive Protein and Type 2 Diabetes in a Multiethnic Population

Findings support the emerging concept that Lp(a) may function as a molecular-inflammatory mediator potentially contributing to residual cardiovascular risk and highlight the importance of incorporating Lp(a) assessment into cardiometabolic risk stratification, particularly in high-risk populations.

Mohammad G. Qaddoumi, A. Albatineh, I. Alkhairi et al. · 0 citations
Review Open access Aug 2026

Suggestive genome-wide associations with inflammatory biomarkers in an admixed population, including a missense variant in the OR6K6 olfactory receptor gene associated with MCP-1

New SNPs linked to inflammatory biomarkers in a highly admixed Brazilian population are identified, including a missense variant in an olfactory receptor gene linked to MCP-1, which may be biologically important for inflammation and could affect the risk of cardiometabolic diseases.

J. Leite, G. F. L. Pascoal, G. B. S. Duarte et al. · 0 citations
Open access Sep 2026

Genetic and Clinical Determinants of Variation in Drug Response in Type 2 Diabetes: Insights From the Scottish and UK Biobank Cohorts

The contributions of clinical characteristics and genetic predisposition as measured through partitioned polygenic risk scores (pPRS) to variation in glycemic response to glucose‐lowering therapies are quantified.

S. Garg, R. Kitchen, R. Gupta et al. · 0 citations
Open access Jul 2026

Glycemic variability, atherosclerosis, and arterial stiffness in persons with type 2 diabetes mellitus: A Mendelian randomization and epidemiologic study

Investigation of visit-to-visit variability in HbA1c and fasting plasma glucose (FPG) and atherosclerotic markers in persons with type 2 diabetes mellitus provides evidence that FPG variability is significantly associated with atherosclerosis, as indicated by the ABI.

Tsai-Chung Li, Chia-Ing Li, Chiu-Shong Liu et al. · 0 citations
Open access Sep 2026

Associations of lipoprotein(a) with fasting insulin, fasting glucose, and incident type 2 diabetes: a prospective analysis from the Young Finns Study

Inverse associations between Lp(a) and fasting glucose were observed in males and higher adult Lp(a) concentrations were prospectively associated with lower risk of incident type 2 diabetes, in the prospective Young Finns Study cohort.

M. Knuuti, N. Kartiosuo, K. Pahkala et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.